Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies
Health care for people living with HIV has improved substantially in the past two decades. Robust estimates of how these improvements have affected prognosis and life expectancy are of utmost importance to patients, clinicians, and health-care planners. We examined changes in 3 year survival and lif...
Uloženo v:
| Vydáno v: | The lancet HIV Ročník 4; číslo 8; s. e349 |
|---|---|
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
Netherlands
01.08.2017
|
| Témata: | |
| ISSN: | 2352-3018, 2352-3018 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Health care for people living with HIV has improved substantially in the past two decades. Robust estimates of how these improvements have affected prognosis and life expectancy are of utmost importance to patients, clinicians, and health-care planners. We examined changes in 3 year survival and life expectancy of patients starting combination antiretroviral therapy (ART) between 1996 and 2013.
We analysed data from 18 European and North American HIV-1 cohorts. Patients (aged ≥16 years) were eligible for this analysis if they had started ART with three or more drugs between 1996 and 2010 and had at least 3 years of potential follow-up. We estimated adjusted (for age, sex, AIDS, risk group, CD4 cell count, and HIV-1 RNA at start of ART) all-cause and cause-specific mortality hazard ratios (HRs) for the first year after ART initiation and the second and third years after ART initiation in four calendar periods (1996-99, 2000-03 [comparator], 2004-07, 2008-10). We estimated life expectancy by calendar period of initiation of ART.
88 504 patients were included in our analyses, of whom 2106 died during the first year of ART and 2302 died during the second or third year of ART. Patients starting ART in 2008-10 had lower all-cause mortality in the first year after ART initiation than did patients starting ART in 2000-03 (adjusted HR 0·71, 95% CI 0·61-0·83). All-cause mortality in the second and third years after initiation of ART was also lower in patients who started ART in 2008-10 than in those who started in 2000-03 (0·57, 0·49-0·67); this decrease was not fully explained by viral load and CD4 cell count at 1 year. Rates of non-AIDS deaths were lower in patients who started ART in 2008-10 (vs 2000-03) in the first year (0·48, 0·34-0·67) and second and third years (0·29, 0·21-0·40) after initiation of ART. Between 1996 and 2010, life expectancy in 20-year-old patients starting ART increased by about 9 years in women and 10 years in men.
Even in the late ART era, survival during the first 3 years of ART continues to improve, which probably reflects transition to less toxic antiretroviral drugs, improved adherence, prophylactic measures, and management of comorbidity. Prognostic models and life expectancy estimates should be updated to account for these improvements.
UK Medical Research Council, UK Department for International Development, EU EDCTP2 programme. |
|---|---|
| AbstractList | Health care for people living with HIV has improved substantially in the past two decades. Robust estimates of how these improvements have affected prognosis and life expectancy are of utmost importance to patients, clinicians, and health-care planners. We examined changes in 3 year survival and life expectancy of patients starting combination antiretroviral therapy (ART) between 1996 and 2013.BACKGROUNDHealth care for people living with HIV has improved substantially in the past two decades. Robust estimates of how these improvements have affected prognosis and life expectancy are of utmost importance to patients, clinicians, and health-care planners. We examined changes in 3 year survival and life expectancy of patients starting combination antiretroviral therapy (ART) between 1996 and 2013.We analysed data from 18 European and North American HIV-1 cohorts. Patients (aged ≥16 years) were eligible for this analysis if they had started ART with three or more drugs between 1996 and 2010 and had at least 3 years of potential follow-up. We estimated adjusted (for age, sex, AIDS, risk group, CD4 cell count, and HIV-1 RNA at start of ART) all-cause and cause-specific mortality hazard ratios (HRs) for the first year after ART initiation and the second and third years after ART initiation in four calendar periods (1996-99, 2000-03 [comparator], 2004-07, 2008-10). We estimated life expectancy by calendar period of initiation of ART.METHODSWe analysed data from 18 European and North American HIV-1 cohorts. Patients (aged ≥16 years) were eligible for this analysis if they had started ART with three or more drugs between 1996 and 2010 and had at least 3 years of potential follow-up. We estimated adjusted (for age, sex, AIDS, risk group, CD4 cell count, and HIV-1 RNA at start of ART) all-cause and cause-specific mortality hazard ratios (HRs) for the first year after ART initiation and the second and third years after ART initiation in four calendar periods (1996-99, 2000-03 [comparator], 2004-07, 2008-10). We estimated life expectancy by calendar period of initiation of ART.88 504 patients were included in our analyses, of whom 2106 died during the first year of ART and 2302 died during the second or third year of ART. Patients starting ART in 2008-10 had lower all-cause mortality in the first year after ART initiation than did patients starting ART in 2000-03 (adjusted HR 0·71, 95% CI 0·61-0·83). All-cause mortality in the second and third years after initiation of ART was also lower in patients who started ART in 2008-10 than in those who started in 2000-03 (0·57, 0·49-0·67); this decrease was not fully explained by viral load and CD4 cell count at 1 year. Rates of non-AIDS deaths were lower in patients who started ART in 2008-10 (vs 2000-03) in the first year (0·48, 0·34-0·67) and second and third years (0·29, 0·21-0·40) after initiation of ART. Between 1996 and 2010, life expectancy in 20-year-old patients starting ART increased by about 9 years in women and 10 years in men.FINDINGS88 504 patients were included in our analyses, of whom 2106 died during the first year of ART and 2302 died during the second or third year of ART. Patients starting ART in 2008-10 had lower all-cause mortality in the first year after ART initiation than did patients starting ART in 2000-03 (adjusted HR 0·71, 95% CI 0·61-0·83). All-cause mortality in the second and third years after initiation of ART was also lower in patients who started ART in 2008-10 than in those who started in 2000-03 (0·57, 0·49-0·67); this decrease was not fully explained by viral load and CD4 cell count at 1 year. Rates of non-AIDS deaths were lower in patients who started ART in 2008-10 (vs 2000-03) in the first year (0·48, 0·34-0·67) and second and third years (0·29, 0·21-0·40) after initiation of ART. Between 1996 and 2010, life expectancy in 20-year-old patients starting ART increased by about 9 years in women and 10 years in men.Even in the late ART era, survival during the first 3 years of ART continues to improve, which probably reflects transition to less toxic antiretroviral drugs, improved adherence, prophylactic measures, and management of comorbidity. Prognostic models and life expectancy estimates should be updated to account for these improvements.INTERPRETATIONEven in the late ART era, survival during the first 3 years of ART continues to improve, which probably reflects transition to less toxic antiretroviral drugs, improved adherence, prophylactic measures, and management of comorbidity. Prognostic models and life expectancy estimates should be updated to account for these improvements.UK Medical Research Council, UK Department for International Development, EU EDCTP2 programme.FUNDINGUK Medical Research Council, UK Department for International Development, EU EDCTP2 programme. Health care for people living with HIV has improved substantially in the past two decades. Robust estimates of how these improvements have affected prognosis and life expectancy are of utmost importance to patients, clinicians, and health-care planners. We examined changes in 3 year survival and life expectancy of patients starting combination antiretroviral therapy (ART) between 1996 and 2013. We analysed data from 18 European and North American HIV-1 cohorts. Patients (aged ≥16 years) were eligible for this analysis if they had started ART with three or more drugs between 1996 and 2010 and had at least 3 years of potential follow-up. We estimated adjusted (for age, sex, AIDS, risk group, CD4 cell count, and HIV-1 RNA at start of ART) all-cause and cause-specific mortality hazard ratios (HRs) for the first year after ART initiation and the second and third years after ART initiation in four calendar periods (1996-99, 2000-03 [comparator], 2004-07, 2008-10). We estimated life expectancy by calendar period of initiation of ART. 88 504 patients were included in our analyses, of whom 2106 died during the first year of ART and 2302 died during the second or third year of ART. Patients starting ART in 2008-10 had lower all-cause mortality in the first year after ART initiation than did patients starting ART in 2000-03 (adjusted HR 0·71, 95% CI 0·61-0·83). All-cause mortality in the second and third years after initiation of ART was also lower in patients who started ART in 2008-10 than in those who started in 2000-03 (0·57, 0·49-0·67); this decrease was not fully explained by viral load and CD4 cell count at 1 year. Rates of non-AIDS deaths were lower in patients who started ART in 2008-10 (vs 2000-03) in the first year (0·48, 0·34-0·67) and second and third years (0·29, 0·21-0·40) after initiation of ART. Between 1996 and 2010, life expectancy in 20-year-old patients starting ART increased by about 9 years in women and 10 years in men. Even in the late ART era, survival during the first 3 years of ART continues to improve, which probably reflects transition to less toxic antiretroviral drugs, improved adherence, prophylactic measures, and management of comorbidity. Prognostic models and life expectancy estimates should be updated to account for these improvements. UK Medical Research Council, UK Department for International Development, EU EDCTP2 programme. |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28501495$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkE1LAzEQhoNUtNb-BCVHPazmezfepKgtCB6qXkuSTjWy3axJttKzf9z1E08zDM88M7wHaNCEBhA6ouSMEqrO54xLVnBCqxNannJClCqqHTT8Gw_-9ftonNILIYRKUUnB9tA-qyShQsshep93ceM3psZhhaezx6INyWe_Adya7KHJCadsYvbNEzZN9hFyDBsf-4X8DNG0W2whvwE0mGqtemaJGaH8AhvsQl0bG6L58pnG1Nvk0-chF55DzL25W3pIh2h3ZeoE4586Qg_XV_eTaXF7dzObXN4WTgmWC-qYsqUAUzrNARgTipcroa2Vgi5Bcllqprm1vLLKgiWcOakkVEo6Jw1hI3Ty7W1jeO0g5cXaJwf9kw2ELi1opTWlXArRo8c_aGfXsFy00a9N3C5-g2MfKiVz8Q |
| CitedBy_id | crossref_primary_10_1097_COH_0000000000000670 crossref_primary_10_1097_GME_0000000000002287 crossref_primary_10_3389_fmicb_2017_02368 crossref_primary_10_3389_fpubh_2023_1084210 crossref_primary_10_1016_j_bcp_2020_114231 crossref_primary_10_1038_s41598_020_79002_w crossref_primary_10_1080_09540121_2025_2530411 crossref_primary_10_1080_17512433_2024_2350968 crossref_primary_10_1089_apc_2017_0238 crossref_primary_10_1093_cid_ciz670 crossref_primary_10_3389_fimmu_2019_01966 crossref_primary_10_1016_S2352_3018_22_00046_7 crossref_primary_10_1097_QAD_0000000000002345 crossref_primary_10_1097_QAD_0000000000003434 crossref_primary_10_1097_QAD_0000000000003552 crossref_primary_10_1097_QAD_0000000000003550 crossref_primary_10_1371_journal_pone_0283648 crossref_primary_10_1038_s41598_021_02556_w crossref_primary_10_1111_hiv_13205 crossref_primary_10_1111_hiv_13447 crossref_primary_10_5888_pcd17_190359 crossref_primary_10_1371_journal_pone_0246338 crossref_primary_10_1136_bmjopen_2020_045158 crossref_primary_10_1089_aid_2020_0128 crossref_primary_10_3390_jcm10030392 crossref_primary_10_1097_QCO_0000000000000890 crossref_primary_10_3389_fpubh_2022_916224 crossref_primary_10_3389_fimmu_2020_00519 crossref_primary_10_1080_1061186X_2017_1419363 crossref_primary_10_3389_fmicb_2019_01227 crossref_primary_10_1093_ajhp_zxz059 crossref_primary_10_1016_j_drugalcdep_2020_108003 crossref_primary_10_1097_ANS_0000000000000469 crossref_primary_10_3390_cells10082067 crossref_primary_10_1007_s12672_021_00397_7 crossref_primary_10_1097_QAD_0000000000003569 crossref_primary_10_1097_QAD_0000000000002358 crossref_primary_10_1002_jia2_25986 crossref_primary_10_1097_QAD_0000000000002599 crossref_primary_10_1111_jrh_12732 crossref_primary_10_1097_JNC_0000000000000355 crossref_primary_10_1128_AAC_02275_17 crossref_primary_10_1177_13596535221112729 crossref_primary_10_1097_JNC_0000000000000235 crossref_primary_10_1007_s10461_019_02423_w crossref_primary_10_1097_QAI_0000000000003326 crossref_primary_10_1136_bmjgh_2018_001007 crossref_primary_10_1371_journal_pone_0249515 crossref_primary_10_1007_s15010_018_1248_8 crossref_primary_10_1128_AAC_01039_21 crossref_primary_10_1007_s11065_021_09483_7 crossref_primary_10_1093_sleep_zsac212 crossref_primary_10_1521_aeap_2025_37_2_89 crossref_primary_10_1111_hiv_13471 crossref_primary_10_1136_sextrans_2021_055271 crossref_primary_10_1089_apc_2018_0190 crossref_primary_10_1161_CIRCULATIONAHA_122_063040 crossref_primary_10_1161_JAHA_119_013466 crossref_primary_10_1016_j_ajog_2019_09_008 crossref_primary_10_1016_j_ebiom_2022_103906 crossref_primary_10_1016_j_ijantimicag_2023_106897 crossref_primary_10_1002_jia2_25776 crossref_primary_10_1177_20420986221080795 crossref_primary_10_1016_j_ijantimicag_2022_106696 crossref_primary_10_1097_QAD_0000000000002129 crossref_primary_10_3389_fmicb_2023_1270258 crossref_primary_10_1155_2022_5884845 crossref_primary_10_1097_QAD_0000000000003331 crossref_primary_10_4253_wjge_v15_i9_545 crossref_primary_10_1089_aid_2019_0143 crossref_primary_10_1007_s40121_021_00522_7 crossref_primary_10_1097_JSM_0000000000001350 crossref_primary_10_3389_fmed_2020_586390 crossref_primary_10_1007_s10461_017_1864_9 crossref_primary_10_1007_s12350_020_02522_5 crossref_primary_10_1111_hiv_13221 crossref_primary_10_1186_s12879_022_07451_x crossref_primary_10_1097_COH_0000000000000782 crossref_primary_10_1186_s12913_020_05381_5 crossref_primary_10_2196_35785 crossref_primary_10_3389_fcimb_2021_658848 crossref_primary_10_1111_hiv_13460 crossref_primary_10_1007_s11904_021_00548_z crossref_primary_10_1080_17290376_2021_1989021 crossref_primary_10_1002_jia2_25400 crossref_primary_10_1016_j_medmal_2020_10_016 crossref_primary_10_1080_09540121_2021_1887445 crossref_primary_10_1093_cid_ciaa918 crossref_primary_10_1093_cid_ciz341 crossref_primary_10_1097_QAD_0000000000002257 crossref_primary_10_1093_ntr_ntaa262 crossref_primary_10_1097_QAI_0000000000002455 crossref_primary_10_1097_QAD_0000000000002372 crossref_primary_10_1097_QAD_0000000000002493 crossref_primary_10_1097_QAD_0000000000003461 crossref_primary_10_1080_15381501_2019_1638334 crossref_primary_10_1111_hiv_13216 crossref_primary_10_1007_s11904_023_00648_y crossref_primary_10_1016_S2352_3018_17_30134_0 crossref_primary_10_1111_hiv_13010 crossref_primary_10_1016_j_hsr_2023_100114 crossref_primary_10_1016_j_jiph_2025_102661 crossref_primary_10_1097_QAI_0000000000002207 crossref_primary_10_3389_fimmu_2021_634489 crossref_primary_10_1080_03007995_2023_2262379 crossref_primary_10_1093_jac_dkaf137 crossref_primary_10_1016_j_puhe_2023_08_030 crossref_primary_10_1097_QAD_0000000000002387 crossref_primary_10_1080_09638288_2018_1448469 crossref_primary_10_3390_ijerph18073437 crossref_primary_10_3390_v16020219 crossref_primary_10_1097_QAD_0000000000003594 crossref_primary_10_36793_psicumex_v15i1_687 crossref_primary_10_1111_hiv_13127 crossref_primary_10_3389_fphar_2019_01472 crossref_primary_10_1371_journal_pone_0317674 crossref_primary_10_3390_biomedicines11102780 crossref_primary_10_1097_QAD_0000000000004210 crossref_primary_10_1016_j_bonr_2021_101128 crossref_primary_10_1371_journal_ppat_1007246 crossref_primary_10_1016_j_bulcan_2020_01_001 crossref_primary_10_1136_bmjopen_2024_086866 crossref_primary_10_1007_s10900_020_00844_6 crossref_primary_10_1016_j_xnsj_2024_100577 crossref_primary_10_3389_fphar_2021_593434 crossref_primary_10_1080_09540121_2020_1761938 crossref_primary_10_1016_j_clinthera_2022_04_007 crossref_primary_10_1080_17512433_2018_1453805 crossref_primary_10_1089_apc_2018_0052 crossref_primary_10_1097_QCO_0000000000000615 crossref_primary_10_1016_S0140_6736_19_30701_9 crossref_primary_10_1002_jvc2_430 crossref_primary_10_3389_fimmu_2025_1475160 crossref_primary_10_1016_j_lanwpc_2021_100269 crossref_primary_10_1080_14787210_2020_1729742 crossref_primary_10_1007_s40262_021_01005_1 crossref_primary_10_1172_JCI136502 crossref_primary_10_1016_S2352_3018_20_30235_6 crossref_primary_10_3389_fendo_2022_847778 crossref_primary_10_3390_life14111367 crossref_primary_10_1128_JVI_00486_20 crossref_primary_10_1016_j_omtn_2020_07_016 crossref_primary_10_1016_S2352_3018_23_00272_2 crossref_primary_10_1093_infdis_jiz185 crossref_primary_10_1007_s40271_020_00413_y crossref_primary_10_1089_aid_2020_0295 crossref_primary_10_1080_17512433_2019_1698946 crossref_primary_10_2188_jea_JE20210150 crossref_primary_10_1177_23259582221144448 crossref_primary_10_1177_09564624211020995 crossref_primary_10_3390_jcm12041458 crossref_primary_10_1093_cid_ciy045 crossref_primary_10_1016_j_coviro_2017_12_001 crossref_primary_10_1136_ejhpharm_2020_002330 crossref_primary_10_1177_0956462418758116 crossref_primary_10_1007_s00590_024_03872_3 crossref_primary_10_1371_journal_ppat_1011844 crossref_primary_10_1007_s10461_018_2303_2 crossref_primary_10_1097_QAD_0000000000002165 crossref_primary_10_1136_bmjopen_2018_026827 crossref_primary_10_1097_QAD_0000000000002285 crossref_primary_10_3389_fpsyt_2023_1081867 crossref_primary_10_1089_aid_2019_0100 crossref_primary_10_3390_diseases7040056 crossref_primary_10_1097_QAI_0000000000003515 crossref_primary_10_1089_aid_2019_0114 crossref_primary_10_1097_QAD_0000000000002171 crossref_primary_10_57264_cer_2024_0231 crossref_primary_10_1038_s41585_018_0038_5 crossref_primary_10_1007_s00134_020_05945_3 crossref_primary_10_1007_s10461_020_02871_9 crossref_primary_10_1016_S2352_3018_19_30334_0 crossref_primary_10_1371_journal_pone_0301335 crossref_primary_10_1097_QAD_0000000000004118 crossref_primary_10_1016_j_jogc_2017_11_031 crossref_primary_10_1089_aid_2020_0182 crossref_primary_10_1371_journal_pone_0267271 crossref_primary_10_1097_QAI_0000000000002416 crossref_primary_10_1177_0272989X17738753 crossref_primary_10_1007_s40121_021_00445_3 crossref_primary_10_1080_07853890_2024_2305692 crossref_primary_10_1165_rcmb_2018_0327ED crossref_primary_10_1007_s13365_018_0660_2 crossref_primary_10_1002_jbm4_10446 crossref_primary_10_1080_17512433_2019_1627200 crossref_primary_10_1097_QAI_0000000000002655 crossref_primary_10_1111_hiv_13017 crossref_primary_10_1093_ehjopen_oeab040 crossref_primary_10_1155_2021_6697404 crossref_primary_10_1186_s12877_022_03411_x crossref_primary_10_1186_s12879_025_11270_1 crossref_primary_10_1186_s12889_021_10196_y crossref_primary_10_1371_journal_ppat_1008663 crossref_primary_10_2147_PPA_S272211 crossref_primary_10_1186_s12981_021_00413_4 crossref_primary_10_1016_j_athoracsur_2020_05_133 crossref_primary_10_1016_j_medmal_2020_04_004 crossref_primary_10_1093_ofid_ofaa316 crossref_primary_10_1016_j_bjid_2023_102757 crossref_primary_10_1371_journal_pone_0257639 crossref_primary_10_1016_j_antiviral_2025_106216 crossref_primary_10_1136_bmjopen_2023_081129 crossref_primary_10_3389_fphar_2023_1097862 crossref_primary_10_1097_QCO_0000000000000701 crossref_primary_10_1016_j_ijid_2021_06_032 crossref_primary_10_1080_09540121_2020_1736259 crossref_primary_10_3138_jammi_2019_0013 crossref_primary_10_7326_M21_0065 crossref_primary_10_1007_s15010_020_01574_6 crossref_primary_10_1056_NEJMe2204376 crossref_primary_10_1097_GME_0000000000001914 crossref_primary_10_1038_s41598_024_64902_y crossref_primary_10_3390_v16020259 crossref_primary_10_36290_der_2022_020 crossref_primary_10_1177_2325958219883334 crossref_primary_10_1186_s12889_019_6716_2 crossref_primary_10_1016_j_jfma_2019_12_020 crossref_primary_10_1093_cid_ciae228 crossref_primary_10_3389_fmicb_2018_01754 crossref_primary_10_1016_j_jinf_2018_11_008 crossref_primary_10_1038_s41467_025_57668_y crossref_primary_10_1097_QAD_0000000000004259 crossref_primary_10_1089_bari_2019_0065 crossref_primary_10_1097_QAD_0000000000004018 crossref_primary_10_1097_QAD_0000000000004019 crossref_primary_10_1093_infdis_jiac128 crossref_primary_10_1093_infdis_jiz650 crossref_primary_10_29333_ejgm_14597 crossref_primary_10_1002_jmv_27387 crossref_primary_10_3390_ijerph18179063 crossref_primary_10_1186_s12913_019_4173_3 crossref_primary_10_1186_s12879_023_08164_5 crossref_primary_10_1186_s12916_024_03262_w crossref_primary_10_36290_med_2021_028 crossref_primary_10_1016_j_arabjc_2024_105995 crossref_primary_10_3390_cancers16010070 crossref_primary_10_1097_QAI_0000000000003047 crossref_primary_10_1016_j_jmii_2019_03_008 crossref_primary_10_1007_s10461_020_02848_8 crossref_primary_10_1097_QAI_0000000000003169 crossref_primary_10_1111_hiv_13159 crossref_primary_10_1080_09540121_2022_2147478 crossref_primary_10_1002_prp2_1093 crossref_primary_10_1089_apc_2018_0015 crossref_primary_10_1371_journal_pone_0292740 crossref_primary_10_1371_journal_pone_0308859 crossref_primary_10_1186_s42269_024_01248_5 crossref_primary_10_3389_fimmu_2021_752782 crossref_primary_10_1002_ijc_32895 crossref_primary_10_1007_s11135_021_01160_4 crossref_primary_10_1016_j_vascn_2022_107157 crossref_primary_10_1038_s41598_024_68909_3 crossref_primary_10_1161_JAHA_118_009996 crossref_primary_10_1080_09540121_2019_1576848 crossref_primary_10_1007_s10461_018_2206_2 crossref_primary_10_1093_jac_dkae465 crossref_primary_10_1080_08897077_2019_1706695 crossref_primary_10_3390_v16020239 crossref_primary_10_1371_journal_pone_0282857 crossref_primary_10_3390_vaccines10060891 crossref_primary_10_3389_fendo_2023_1201696 crossref_primary_10_3390_v14081677 crossref_primary_10_1080_09540121_2021_1934379 crossref_primary_10_1371_journal_pone_0269779 crossref_primary_10_1097_MD_0000000000026663 crossref_primary_10_1016_j_jconrel_2019_09_001 crossref_primary_10_1097_QAD_0000000000004158 crossref_primary_10_1186_s12879_024_09595_4 crossref_primary_10_2989_16085906_2018_1439512 crossref_primary_10_1080_16066359_2018_1516756 crossref_primary_10_1007_s40266_022_01003_3 crossref_primary_10_1016_j_kint_2023_07_022 crossref_primary_10_1080_09638288_2019_1621395 crossref_primary_10_1186_s12879_020_4837_y crossref_primary_10_1016_j_japh_2023_12_023 crossref_primary_10_1093_infdis_jiae644 crossref_primary_10_9778_cmajo_20200249 crossref_primary_10_1097_CXA_0000000000000031 crossref_primary_10_1093_cei_uxab013 crossref_primary_10_2147_HIV_S421523 crossref_primary_10_1002_rcm_8058 crossref_primary_10_1097_QAI_0000000000002177 crossref_primary_10_1186_s12879_025_10940_4 crossref_primary_10_1093_jac_dkac391 crossref_primary_10_1016_j_ijid_2022_07_037 crossref_primary_10_1186_s12981_024_00634_3 crossref_primary_10_3390_curroncol32070389 crossref_primary_10_1007_s41999_018_0139_y crossref_primary_10_1016_j_isci_2023_108259 crossref_primary_10_1097_QAI_0000000000002043 crossref_primary_10_1186_s12879_024_10388_y crossref_primary_10_1177_15248399231160758 crossref_primary_10_1111_hiv_13093 crossref_primary_10_2147_HIV_S283059 crossref_primary_10_1007_s11096_021_01242_1 crossref_primary_10_1371_journal_pone_0194220 crossref_primary_10_1001_jamapediatrics_2018_0389 crossref_primary_10_3389_fpubh_2020_00036 crossref_primary_10_3390_pathogens10070806 crossref_primary_10_1093_ofid_ofab330 crossref_primary_10_1136_bmjopen_2022_062008 crossref_primary_10_1038_s41467_019_10884_9 crossref_primary_10_1016_S2352_3018_23_00028_0 crossref_primary_10_1080_23744235_2019_1565415 crossref_primary_10_1128_aac_01941_21 crossref_primary_10_1016_S2352_3018_22_00098_4 crossref_primary_10_3390_biomedicines10081823 crossref_primary_10_1016_j_bulcan_2021_01_026 crossref_primary_10_1111_hiv_13082 crossref_primary_10_1007_s11481_020_09964_1 crossref_primary_10_32712_2446_4775_2025_1749 crossref_primary_10_1038_s41598_022_10263_3 crossref_primary_10_1186_s12879_021_05850_0 crossref_primary_10_4102_sajhivmed_v26i1_1646 crossref_primary_10_1371_journal_pone_0257731 crossref_primary_10_1089_aid_2022_0186 crossref_primary_10_1093_jac_dkad348 crossref_primary_10_1111_jvh_13863 crossref_primary_10_1080_22221751_2025_2539198 crossref_primary_10_1111_bcp_13837 crossref_primary_10_1007_s10508_018_1213_8 crossref_primary_10_1007_s41999_019_00160_w crossref_primary_10_3389_fphar_2023_1122018 crossref_primary_10_1007_s13365_018_0702_9 crossref_primary_10_1007_s40746_023_00278_x crossref_primary_10_1016_j_surge_2021_04_005 crossref_primary_10_1111_hiv_70068 crossref_primary_10_1016_S0140_6736_18_31311_4 crossref_primary_10_3389_fimmu_2021_793375 crossref_primary_10_1371_journal_pone_0277231 crossref_primary_10_1007_s40506_021_00252_x crossref_primary_10_12968_hmed_2017_78_9_516 crossref_primary_10_3389_fimmu_2019_02999 crossref_primary_10_1177_0898264320925323 crossref_primary_10_1080_09540121_2021_1929815 crossref_primary_10_3390_vaccines9020176 crossref_primary_10_1172_JCI99884 crossref_primary_10_1016_j_hermed_2021_100477 crossref_primary_10_1177_00333549211023266 crossref_primary_10_3389_fpubh_2025_1614619 crossref_primary_10_1186_s12955_020_01643_2 crossref_primary_10_1186_s12981_020_00280_5 crossref_primary_10_3390_v15081740 crossref_primary_10_1016_j_dsx_2022_102679 crossref_primary_10_1128_spectrum_00532_23 crossref_primary_10_1093_cid_ciab1069 crossref_primary_10_1177_2042098620976953 crossref_primary_10_1186_s12889_019_6838_6 crossref_primary_10_1177_09564624211043351 crossref_primary_10_1097_JSM_0000000000000738 crossref_primary_10_1016_j_medcle_2023_12_010 crossref_primary_10_1097_QAI_0000000000003585 crossref_primary_10_1080_09540121_2022_2148626 crossref_primary_10_1124_jpet_119_258384 crossref_primary_10_1080_17441692_2021_2002923 crossref_primary_10_7759_cureus_15327 crossref_primary_10_1136_bmjopen_2022_071285 crossref_primary_10_1097_QAI_0000000000003107 crossref_primary_10_1089_apc_2019_0013 crossref_primary_10_1007_s13365_021_01048_x crossref_primary_10_1093_oncolo_oyad056 crossref_primary_10_1371_journal_pone_0319010 crossref_primary_10_1371_journal_pone_0232977 crossref_primary_10_1007_s13365_023_01116_4 crossref_primary_10_1080_09540121_2020_1798336 crossref_primary_10_1097_QAI_0000000000001834 crossref_primary_10_4330_wjc_v14_i7_427 crossref_primary_10_36469_jheor_2020_13457 crossref_primary_10_5694_mja2_50114 crossref_primary_10_1007_s10840_022_01233_w crossref_primary_10_1007_s11298_019_7094_x crossref_primary_10_3390_ijerph22060840 crossref_primary_10_1128_AAC_02016_18 crossref_primary_10_1093_aje_kwz236 crossref_primary_10_1007_s10461_021_03466_8 crossref_primary_10_1093_cid_ciz1243 crossref_primary_10_1007_s10461_025_04647_5 crossref_primary_10_1186_s12889_023_15662_3 crossref_primary_10_1016_j_ajog_2019_06_021 crossref_primary_10_1080_09540121_2018_1563281 crossref_primary_10_1097_QAD_0000000000001819 crossref_primary_10_2196_15013 crossref_primary_10_1093_aje_kwz232 crossref_primary_10_3389_fmed_2025_1630960 crossref_primary_10_3390_polym14153090 crossref_primary_10_1161_CIRCULATIONAHA_117_032647 crossref_primary_10_1016_j_str_2018_06_001 crossref_primary_10_1007_s10461_018_2236_9 crossref_primary_10_1177_1060028019833038 crossref_primary_10_1186_s12955_020_01451_8 crossref_primary_10_1080_16549716_2020_1715324 crossref_primary_10_3390_v15051170 crossref_primary_10_1016_j_eimce_2024_12_003 crossref_primary_10_1177_10600280231156624 crossref_primary_10_1007_s11481_019_09868_9 crossref_primary_10_1371_journal_pgen_1010791 crossref_primary_10_1016_j_clinthera_2025_05_015 crossref_primary_10_1177_0956462420945948 crossref_primary_10_1093_ofid_ofy121 crossref_primary_10_1097_GME_0000000000001730 crossref_primary_10_1177_17455057231170061 crossref_primary_10_1111_joim_13008 crossref_primary_10_1164_rccm_201711_2271ED crossref_primary_10_1177_87551225251333698 crossref_primary_10_1097_QAD_0000000000001829 crossref_primary_10_2174_1874613601812010117 crossref_primary_10_2147_IDR_S251619 crossref_primary_10_11124_JBIES_20_00190 crossref_primary_10_1177_23259582211005628 crossref_primary_10_1089_aid_2018_0296 crossref_primary_10_1111_imj_13673 crossref_primary_10_1016_j_nurpra_2021_08_013 crossref_primary_10_1016_j_hlpt_2024_100853 crossref_primary_10_1071_SH24056 crossref_primary_10_1007_s10157_019_01768_9 crossref_primary_10_1128_AAC_00935_21 crossref_primary_10_1089_apc_2020_0262 crossref_primary_10_3389_fonc_2022_847710 crossref_primary_10_1016_j_cmi_2020_11_019 crossref_primary_10_1080_17513758_2022_2113828 crossref_primary_10_1177_09564624241301491 crossref_primary_10_3389_fpubh_2023_1161503 crossref_primary_10_1177_23259582251370236 crossref_primary_10_1097_QAD_0000000000001967 crossref_primary_10_1371_journal_pone_0274031 crossref_primary_10_1038_s43856_025_00833_7 crossref_primary_10_1093_jac_dkaa254 crossref_primary_10_1111_bph_14589 crossref_primary_10_1080_13697137_2023_2194528 crossref_primary_10_1111_1348_0421_12862 crossref_primary_10_1177_0956462420904299 crossref_primary_10_1177_2325958220935267 crossref_primary_10_1097_01_NAJ_0000580156_27946_e4 crossref_primary_10_1136_bmjopen_2023_078694 crossref_primary_10_1177_1358863X18789783 crossref_primary_10_1016_j_cjca_2018_12_020 crossref_primary_10_1097_QAI_0000000000003096 crossref_primary_10_1097_QAI_0000000000003095 crossref_primary_10_1172_JCI189574 crossref_primary_10_1016_j_jviromet_2019_05_012 crossref_primary_10_1093_cid_ciab563 crossref_primary_10_1111_jdv_17139 crossref_primary_10_1097_MD_0000000000038558 crossref_primary_10_1007_s10067_020_05500_x crossref_primary_10_1097_MD_0000000000013016 crossref_primary_10_3390_jcm10163456 crossref_primary_10_3390_clinpract12060091 crossref_primary_10_1016_j_jviromet_2024_115105 crossref_primary_10_1089_aid_2018_0279 crossref_primary_10_1097_BCO_0000000000000743 crossref_primary_10_1097_QAD_0000000000001848 crossref_primary_10_1177_00333549211061325 crossref_primary_10_1016_S2352_3018_21_00316_7 crossref_primary_10_1007_s40615_021_01126_0 crossref_primary_10_1007_s40121_023_00840_y crossref_primary_10_2174_1874613602014010050 crossref_primary_10_1093_jac_dkab334 crossref_primary_10_1007_s10461_025_04669_z crossref_primary_10_1111_hiv_12833 crossref_primary_10_1093_cid_ciaa1878 crossref_primary_10_3389_fmicb_2018_03352 crossref_primary_10_1093_heapro_daz037 crossref_primary_10_1002_jia2_25274 crossref_primary_10_1176_appi_prcp_20180005 crossref_primary_10_1038_s41572_023_00452_3 crossref_primary_10_1080_09540121_2025_2534126 crossref_primary_10_1016_S2352_3018_22_00094_7 crossref_primary_10_1080_14737167_2024_2384543 crossref_primary_10_5334_gh_1081 crossref_primary_10_1007_s41999_018_0147_y crossref_primary_10_3390_idr17030065 crossref_primary_10_1016_j_annepidem_2020_09_004 crossref_primary_10_1177_09564624241242171 crossref_primary_10_1136_bmjgh_2022_010966 crossref_primary_10_3389_fimmu_2019_02445 crossref_primary_10_1002_hpm_3268 crossref_primary_10_1136_bmjopen_2018_027325 crossref_primary_10_1093_cid_ciz1171 crossref_primary_10_1111_hiv_12701 crossref_primary_10_1136_bmjopen_2021_059294 crossref_primary_10_1111_hiv_12940 crossref_primary_10_1002_hec_3784 crossref_primary_10_1177_10775587231198903 crossref_primary_10_1007_s40121_018_0201_6 crossref_primary_10_1186_s12916_020_01801_9 crossref_primary_10_1016_j_cnur_2017_10_009 crossref_primary_10_1161_ATVBAHA_120_315435 crossref_primary_10_2196_39015 crossref_primary_10_1093_ofid_ofac487 crossref_primary_10_2147_IDR_S246462 crossref_primary_10_1097_QAD_0000000000002839 crossref_primary_10_1093_cid_ciaa1771 crossref_primary_10_1093_infdis_jiy524 crossref_primary_10_2147_JMDH_S392398 crossref_primary_10_1007_s10865_020_00141_6 crossref_primary_10_1097_QAI_0000000000003184 crossref_primary_10_1080_17512433_2024_2344672 crossref_primary_10_1089_aid_2017_0160 crossref_primary_10_1007_s41999_018_0148_x crossref_primary_10_1097_HCO_0000000000001050 crossref_primary_10_1007_s40121_021_00419_5 crossref_primary_10_1097_CM9_0000000000002898 crossref_primary_10_1080_1120009X_2019_1692996 crossref_primary_10_3389_fimmu_2019_01378 crossref_primary_10_3390_diagnostics12112657 crossref_primary_10_2147_PPA_S340621 crossref_primary_10_1097_QAD_0000000000001885 crossref_primary_10_1371_journal_pone_0251252 crossref_primary_10_1089_apc_2024_0202 crossref_primary_10_3389_fphar_2021_603068 crossref_primary_10_1371_journal_pmed_1002424 crossref_primary_10_1093_ofid_ofy216 crossref_primary_10_1002_jia2_25161 crossref_primary_10_1111_hiv_12725 crossref_primary_10_1371_journal_pone_0298542 crossref_primary_10_1093_jpids_piaa020 crossref_primary_10_1111_hiv_12881 crossref_primary_10_1590_0102_311x00212920 crossref_primary_10_1016_j_jpainsymman_2019_03_006 crossref_primary_10_1016_j_ijid_2018_02_009 crossref_primary_10_1016_S2468_2667_24_00304_9 crossref_primary_10_1186_s12879_021_06479_9 crossref_primary_10_1016_j_soncn_2017_12_001 crossref_primary_10_1016_j_antiviral_2020_104784 crossref_primary_10_1093_ofid_ofaf455 crossref_primary_10_1093_jac_dkaa329 crossref_primary_10_1007_s00330_021_07755_7 crossref_primary_10_1016_j_ypmed_2024_108000 crossref_primary_10_1097_QAI_0000000000002647 crossref_primary_10_1080_09540121_2024_2411270 crossref_primary_10_1186_s12913_025_12842_2 crossref_primary_10_1016_j_clbc_2025_03_017 crossref_primary_10_14283_jfa_2021_44 crossref_primary_10_1093_cid_ciy981 crossref_primary_10_1371_journal_pone_0285787 crossref_primary_10_1097_QAD_0000000000002621 crossref_primary_10_1002_jia2_25591 crossref_primary_10_1080_19466315_2024_2375232 crossref_primary_10_1038_s41598_018_37148_8 crossref_primary_10_1371_journal_pone_0271152 crossref_primary_10_2147_HIV_S519939 crossref_primary_10_1016_j_idnow_2024_104990 crossref_primary_10_1002_jia2_26443 crossref_primary_10_1186_s12879_022_07120_z crossref_primary_10_1080_15381501_2022_2029660 crossref_primary_10_1177_08971900211035262 crossref_primary_10_2989_16085906_2021_1887301 crossref_primary_10_1093_infdis_jiz093 crossref_primary_10_1146_annurev_statistics_030718_105057 crossref_primary_10_1016_j_jhep_2020_08_009 crossref_primary_10_1200_GO_22_00016 crossref_primary_10_1177_2325958219888461 crossref_primary_10_1016_j_aca_2019_01_015 crossref_primary_10_3389_fpsyg_2021_681058 crossref_primary_10_1177_2325958219888462 crossref_primary_10_3389_fgene_2022_975397 crossref_primary_10_1093_jnen_nlaf102 crossref_primary_10_1097_QAI_0000000000002759 crossref_primary_10_1080_21642850_2020_1854762 crossref_primary_10_1016_j_sleh_2019_05_002 crossref_primary_10_1038_s41467_024_46606_z crossref_primary_10_3389_fcvm_2025_1498165 crossref_primary_10_1371_journal_pone_0241833 crossref_primary_10_1016_j_bbi_2024_02_023 crossref_primary_10_1097_QAI_0000000000001784 crossref_primary_10_1097_QAI_0000000000001785 crossref_primary_10_1016_j_ijcrp_2022_200151 crossref_primary_10_1007_s00784_022_04818_x crossref_primary_10_1097_QAI_0000000000002635 crossref_primary_10_24857_rgsa_v18n1_109 crossref_primary_10_1016_S2352_3018_19_30239_5 crossref_primary_10_1093_advances_nmaa163 crossref_primary_10_1080_21505594_2023_2278254 crossref_primary_10_1097_QAI_0000000000002627 crossref_primary_10_3389_fneur_2022_962535 crossref_primary_10_1097_QAD_0000000000003856 crossref_primary_10_1016_j_cllc_2023_06_004 crossref_primary_10_1080_14787210_2022_2128766 crossref_primary_10_3389_fpubh_2024_1371675 crossref_primary_10_1093_infdis_jiaf043 crossref_primary_10_3389_fcimb_2025_1466655 crossref_primary_10_3961_jpmph_24_622 crossref_primary_10_1097_QAD_0000000000002761 crossref_primary_10_1007_s10461_019_02438_3 crossref_primary_10_1186_s12879_019_3724_x crossref_primary_10_1038_s41598_022_04866_z crossref_primary_10_1016_j_amjcard_2021_09_042 crossref_primary_10_1007_s00467_020_04756_4 crossref_primary_10_1186_s12879_024_09284_2 crossref_primary_10_1371_journal_ppat_1010396 crossref_primary_10_1002_hsr2_70275 crossref_primary_10_1016_j_coph_2020_12_001 crossref_primary_10_1016_j_jconrel_2021_08_011 crossref_primary_10_1016_S2352_3018_20_30197_1 crossref_primary_10_1093_cid_ciy414 crossref_primary_10_1161_CIRCRESAHA_119_316477 crossref_primary_10_3390_healthcare6010017 crossref_primary_10_1089_aid_2023_0142 crossref_primary_10_3390_v15020517 crossref_primary_10_1093_ecco_jcc_jjy060 crossref_primary_10_1093_ofid_ofz509 crossref_primary_10_1097_QAD_0000000000003625 crossref_primary_10_1177_0310057X20969701 crossref_primary_10_1097_QAD_0000000000003862 crossref_primary_10_1111_hiv_13616 crossref_primary_10_3390_diagnostics10110980 crossref_primary_10_1016_S0140_6736_17_32514_X crossref_primary_10_1186_s12879_020_05593_4 crossref_primary_10_3390_v16040578 crossref_primary_10_3390_ijms22105304 crossref_primary_10_1186_s12981_021_00397_1 crossref_primary_10_1186_s12874_024_02159_9 crossref_primary_10_2147_NRR_S432977 crossref_primary_10_1038_s41598_018_22914_5 crossref_primary_10_1080_09540121_2021_1956414 crossref_primary_10_36469_jheor_2022_30184 crossref_primary_10_1093_cid_ciy786 crossref_primary_10_1128_CMR_00097_18 crossref_primary_10_1007_s10461_021_03265_1 crossref_primary_10_1186_s12879_022_07352_z crossref_primary_10_3390_ph15040482 crossref_primary_10_1097_QAD_0000000000002541 crossref_primary_10_1016_j_immuni_2021_10_021 crossref_primary_10_1097_QAI_0000000000002840 crossref_primary_10_1097_QAI_0000000000002720 crossref_primary_10_1186_s12879_023_08651_9 crossref_primary_10_1007_s15010_024_02402_x crossref_primary_10_3389_fphar_2021_631480 crossref_primary_10_1111_hiv_12792 crossref_primary_10_1371_journal_pone_0240550 crossref_primary_10_1111_dme_14454 crossref_primary_10_1186_s12879_024_09050_4 crossref_primary_10_1161_JAHA_119_012241 crossref_primary_10_1007_s40121_020_00296_4 crossref_primary_10_1007_s40618_017_0812_x crossref_primary_10_3390_ani12111449 crossref_primary_10_1080_09540121_2018_1441971 crossref_primary_10_1097_QAI_0000000000002958 crossref_primary_10_1007_s13555_022_00722_0 crossref_primary_10_1089_aid_2017_0309 crossref_primary_10_1177_2325958220981265 crossref_primary_10_1007_s40265_019_1064_1 crossref_primary_10_1038_s41598_025_99566_9 crossref_primary_10_1158_1078_0432_CCR_18_0544 crossref_primary_10_3389_fimmu_2022_1033098 crossref_primary_10_1136_bmjopen_2018_021507 crossref_primary_10_1038_s41467_021_24673_w crossref_primary_10_1016_j_gore_2022_101069 crossref_primary_10_1128_jcm_00136_24 crossref_primary_10_3389_fcell_2021_716344 crossref_primary_10_1186_s12879_023_08761_4 crossref_primary_10_1093_cid_ciz539 crossref_primary_10_1172_JCI142421 crossref_primary_10_1186_s12874_025_02573_7 crossref_primary_10_1080_09286586_2020_1866021 crossref_primary_10_1016_j_jval_2023_05_010 crossref_primary_10_1080_00498254_2017_1390624 crossref_primary_10_1136_bjsports_2019_100650 crossref_primary_10_1097_QAD_0000000000002689 crossref_primary_10_1016_j_ejogrb_2022_09_031 crossref_primary_10_2174_1874613602115010052 crossref_primary_10_2196_resprot_9439 crossref_primary_10_1371_journal_pone_0262400 crossref_primary_10_3390_microorganisms13081768 crossref_primary_10_1097_QAI_0000000000002941 crossref_primary_10_2105_AJPH_2020_305965 crossref_primary_10_1016_j_diabres_2021_109125 crossref_primary_10_1371_journal_pone_0215591 crossref_primary_10_1093_ofid_ofac196 crossref_primary_10_1093_ofid_ofae132 crossref_primary_10_1177_2325958218822304 crossref_primary_10_1016_j_ijid_2018_10_019 crossref_primary_10_1016_j_lungcan_2023_01_010 crossref_primary_10_1177_23259582221079148 crossref_primary_10_1088_1755_1315_790_1_012039 crossref_primary_10_1186_s12879_024_10182_w crossref_primary_10_1111_hex_12816 crossref_primary_10_1186_s41100_019_0245_4 crossref_primary_10_1002_jia2_25449 crossref_primary_10_3390_ijms22179157 crossref_primary_10_1097_QAD_0000000000002699 crossref_primary_10_1097_QAI_0000000000002938 crossref_primary_10_1097_QAD_0000000000003662 crossref_primary_10_1111_tmi_13871 crossref_primary_10_1007_s41999_019_00168_2 crossref_primary_10_3389_fimmu_2018_03175 crossref_primary_10_1111_hiv_12687 |
| ContentType | Journal Article |
| Contributor | Trickey, Adam Boesecke, Christoph van Sighem, Ard Patterson, Sophie Gill, M John Sterne, Jonathan A C May, Margaret T Cazanave, Charles Hernando, Vicky Crane, Heidi M Shepherd, Leah Vehreschild, Jorg-Janne Saag, Mike Grabar, Sophie Justice, Amy C Lampe, Fiona Montero, Marta Ingle, Suzanne M Monforte, Antonella d'Arminio Zangerle, Robert Obel, Niels Sterling, Timothy Cavassini, Matthias |
| Contributor_xml | – sequence: 1 givenname: Adam surname: Trickey fullname: Trickey, Adam – sequence: 2 givenname: Margaret T surname: May fullname: May, Margaret T – sequence: 3 givenname: Jorg-Janne surname: Vehreschild fullname: Vehreschild, Jorg-Janne – sequence: 4 givenname: Niels surname: Obel fullname: Obel, Niels – sequence: 5 givenname: M John surname: Gill fullname: Gill, M John – sequence: 6 givenname: Heidi M surname: Crane fullname: Crane, Heidi M – sequence: 7 givenname: Christoph surname: Boesecke fullname: Boesecke, Christoph – sequence: 8 givenname: Sophie surname: Patterson fullname: Patterson, Sophie – sequence: 9 givenname: Sophie surname: Grabar fullname: Grabar, Sophie – sequence: 10 givenname: Charles surname: Cazanave fullname: Cazanave, Charles – sequence: 11 givenname: Matthias surname: Cavassini fullname: Cavassini, Matthias – sequence: 12 givenname: Leah surname: Shepherd fullname: Shepherd, Leah – sequence: 13 givenname: Antonella d'Arminio surname: Monforte fullname: Monforte, Antonella d'Arminio – sequence: 14 givenname: Ard surname: van Sighem fullname: van Sighem, Ard – sequence: 15 givenname: Mike surname: Saag fullname: Saag, Mike – sequence: 16 givenname: Fiona surname: Lampe fullname: Lampe, Fiona – sequence: 17 givenname: Vicky surname: Hernando fullname: Hernando, Vicky – sequence: 18 givenname: Marta surname: Montero fullname: Montero, Marta – sequence: 19 givenname: Robert surname: Zangerle fullname: Zangerle, Robert – sequence: 20 givenname: Amy C surname: Justice fullname: Justice, Amy C – sequence: 21 givenname: Timothy surname: Sterling fullname: Sterling, Timothy – sequence: 22 givenname: Suzanne M surname: Ingle fullname: Ingle, Suzanne M – sequence: 23 givenname: Jonathan A C surname: Sterne fullname: Sterne, Jonathan A C |
| Copyright | Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. |
| Copyright_xml | – notice: Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. |
| CorporateAuthor | Antiretroviral Therapy Cohort Collaboration |
| CorporateAuthor_xml | – name: Antiretroviral Therapy Cohort Collaboration |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/S2352-3018(17)30066-8 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 2352-3018 |
| ExternalDocumentID | 28501495 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation | UK Medical Research Council, UK Department for International Development, EU EDCTP2 programme. |
| GrantInformation_xml | – fundername: Medical Research Council grantid: G0700820 – fundername: Medical Research Council grantid: G0100221 – fundername: Medical Research Council grantid: MR/J002380/1 |
| GroupedDBID | -RU .1- .FO 0R~ 1P~ 4.4 457 53G AAEDT AAEDW AALRI AAMRU AAQFI AAXUO ABJNI ACGFS ADBBV AENEX AFRHN AFTJW AGCQF AITUG AJUYK ALMA_UNASSIGNED_HOLDINGS AMRAJ APXCP CGR CUY CVF EBS ECM EFKBS EIF EJD FDB HZ~ M41 NPM O9- OD- OO. ROL Z5R 7X8 |
| ID | FETCH-LOGICAL-c642t-1c26b74ea7c93ee224637f49bb541de53579293bb38b6beb032c565e865cc5a02 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 437 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000406176300011&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2352-3018 |
| IngestDate | Sun Sep 28 07:39:21 EDT 2025 Mon Jul 21 05:50:20 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 8 |
| Language | English |
| License | Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c642t-1c26b74ea7c93ee224637f49bb541de53579293bb38b6beb032c565e865cc5a02 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://www.clinicalkey.es/playcontent/1-s2.0-S2352301817300668 |
| PMID | 28501495 |
| PQID | 1899113544 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1899113544 pubmed_primary_28501495 |
| PublicationCentury | 2000 |
| PublicationDate | 2017-08-01 |
| PublicationDateYYYYMMDD | 2017-08-01 |
| PublicationDate_xml | – month: 08 year: 2017 text: 2017-08-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | The lancet HIV |
| PublicationTitleAlternate | Lancet HIV |
| PublicationYear | 2017 |
| References | 28750744 - Lancet HIV. 2017 Aug;4(8):e330. doi: 10.1016/S2352-3018(17)30134-0. 28750743 - Lancet HIV. 2017 Aug;4(8):e330. doi: 10.1016/S2352-3018(17)30136-4. 28501496 - Lancet HIV. 2017 Aug;4(8):e324-e326. doi: 10.1016/S2352-3018(17)30086-3. |
| References_xml | – reference: 28750743 - Lancet HIV. 2017 Aug;4(8):e330. doi: 10.1016/S2352-3018(17)30136-4. – reference: 28501496 - Lancet HIV. 2017 Aug;4(8):e324-e326. doi: 10.1016/S2352-3018(17)30086-3. – reference: 28750744 - Lancet HIV. 2017 Aug;4(8):e330. doi: 10.1016/S2352-3018(17)30134-0. |
| SSID | ssj0001548542 |
| Score | 2.6075754 |
| Snippet | Health care for people living with HIV has improved substantially in the past two decades. Robust estimates of how these improvements have affected prognosis... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | e349 |
| SubjectTerms | Adolescent Adult Anti-HIV Agents - therapeutic use Antiretroviral Therapy, Highly Active CD4 Lymphocyte Count Cohort Studies Female HIV Infections - drug therapy HIV Infections - epidemiology HIV Infections - mortality HIV Infections - virology HIV-1 - drug effects Humans Life Expectancy Male Risk Factors Survival Analysis Time Factors Viral Load - drug effects Young Adult |
| Title | Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/28501495 https://www.proquest.com/docview/1899113544 |
| Volume | 4 |
| WOSCitedRecordID | wos000406176300011&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEF7UKnjx_agvVvCgh6XNPpKNFxGxVNBSqEpvYXezES9JbdJCz_5xZ5PUehEEL4GEbBI2X2a-mZ3Mh9CF8uNQ8oQTKxMIUGKbEJ3ArtaejKWME6rKJq6PQa8nh8OwXyfc8rqscm4TS0MdZ8blyFseBAaexwTnN6MP4lSj3OpqLaGxjBoMqIxDdTCUixwL0HFR6udQ4BkEsCwXP_G0Bt8HL73gijnnS-TvRLN0OJ3N_z7qFtqoqSa-rbCxjZZsuoPWKvHJ2S76HEzATADQcJbg7sMrqeq3phbXvVZzDMzRNRl4wzD9YBoLl34Yw4Dqp60Zrou8sKsxhnNiDH6eXWOFf6ALrqfqxifuRk6Qd1zgvCpf3EMvnfvnuy6pJRmIgUClIJ6hvg64VYEJmbWuGx0LEh5qLbgXW8FEAHyLac2k9rXVbUYNUEYrfWGMUG26j1bSLLWHCFMK7ETGQhknlUSppq75PLNUqzbn1mui8_nsRgB5t46hUptN8mgxv010UL2iaFT15oioFGXQd_SH0cdonTonXZbznaBGAh-8PUWrZlq85-OzEkuw7fWfvgCKBNL8 |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Survival+of+HIV-positive+patients+starting+antiretroviral+therapy+between+1996+and+2013%3A+a+collaborative+analysis+of+cohort+studies&rft.jtitle=The+lancet+HIV&rft.date=2017-08-01&rft.eissn=2352-3018&rft.volume=4&rft.issue=8&rft.spage=e349&rft_id=info:doi/10.1016%2FS2352-3018%2817%2930066-8&rft_id=info%3Apmid%2F28501495&rft_id=info%3Apmid%2F28501495&rft.externalDocID=28501495 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2352-3018&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2352-3018&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2352-3018&client=summon |